{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cough/management/management/","result":{"pageContext":{"chapter":{"id":"5b0494ec-b87e-560d-b620-7201ec619c71","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field ec56e4d6-8ff5-4eb9-a8e1-0d3e681efb2f --><h2>Scenario: Management</h2><!-- end field ec56e4d6-8ff5-4eb9-a8e1-0d3e681efb2f -->","summary":"Covers the emergency admission of people with cough, the management of acute, subacute, and chronic cough, and the indications for referral.","htmlStringContent":"<!-- begin item abb15e72-7ae5-44e4-a38d-134b1f3cf5ca --><!-- begin field 2fb8c1eb-d8cb-478a-ba89-acbc01583727 --><p>From age 18 years onwards.</p><!-- end field 2fb8c1eb-d8cb-478a-ba89-acbc01583727 --><!-- end item abb15e72-7ae5-44e4-a38d-134b1f3cf5ca -->","topic":{"id":"597a4755-f8ac-5b96-8497-363b3cc83b11","topicId":"fb5757b5-1fbb-4de4-88eb-dceaa28ff6a4","topicName":"Cough","slug":"cough","lastRevised":"Last revised in April 2020","chapters":[{"id":"b1c4f77a-6351-501a-a1c7-e9b9b790dd0e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"58c3fa80-f692-5e09-9798-107097510e80","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6b82117b-5c6e-56c4-a1cf-cf9897e78e4c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a7943b44-8f1a-5762-a584-ea72ac9994ae","slug":"changes","fullItemName":"Changes"},{"id":"89a216ce-25d9-5c48-a029-954d7f5075ee","slug":"update","fullItemName":"Update"}]},{"id":"d19b7219-381d-5f40-9202-19510d25a3da","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"dd50d3f2-69af-57bb-9b83-cebce60d7557","slug":"goals","fullItemName":"Goals"},{"id":"af26a949-741f-5cc2-bc86-8ef7de3619da","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"052ea45f-15ad-5cda-8bbf-62d3b273b773","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5eebc59-66fb-596f-8545-2be70280e5de","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"40cdff51-f5e2-5f16-b601-32a3c8b87df7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f089e701-4d94-5344-90a1-a5ca19be6b1e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"001ac37d-ab25-5075-9a8a-b8ee997fd4e7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5ab2d94f-de9d-51ba-ba3c-b86a74a29e3f","slug":"definition","fullItemName":"Definition"},{"id":"416c9add-44f0-55c0-a6f1-5944578d17fe","slug":"causes","fullItemName":"Causes"},{"id":"5e35f738-0cf1-5c45-9664-f88e8fa9d649","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cd227cb2-2fec-5c29-b246-25e1bfdf96f6","slug":"complications","fullItemName":"Complications"}]},{"id":"98a68170-e5b6-5a0b-8934-5cb43879861b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a405631d-8df1-57ff-aa17-4f8a19ffefcc","slug":"assessment","fullItemName":"Assessment"},{"id":"258678de-311c-50fa-87a3-740d3b24dde3","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"007536a6-3355-59aa-9a0b-1241987ac792","fullItemName":"Management","slug":"management","subChapters":[{"id":"5b0494ec-b87e-560d-b620-7201ec619c71","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"48e7ba3c-c434-5aaa-ab52-be110b15711e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"82e9ad6d-d13d-5be3-ac37-0ccfa69d0e67","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"7bbf1abc-2a2a-5d5e-b185-b9dcd2a2beb1","slug":"nasal-corticosteroids","fullItemName":"Nasal corticosteroids"},{"id":"2ee3fa3c-eeef-5930-b21d-43ffa1feacb4","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"d27986e1-2f31-5785-a5ff-239caa8d789a","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"}]},{"id":"8a0e4f24-6a18-538a-a29e-489dd8483120","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"53aed60c-ff88-5cd9-9224-a8594abca871","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6f4a585d-c73a-5cbf-9bd2-78ec135faf3d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e09be2f4-37ae-5b7f-b0e1-aab8e67520ba","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f3b116d5-844b-57a4-8d25-a9a335e28dfe","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"86a1b1a8-879e-5234-bd21-356872b3cf7f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9da5381b-9708-5921-a51e-96e584f1bc20","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ae9f8564-1ff8-5ddd-9604-4fe339962987","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"007536a6-3355-59aa-9a0b-1241987ac792","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"29c59229-f6be-5e0c-a940-36ab34977c75","slug":"emergency-admission","fullItemName":"Emergency admission","depth":3,"htmlHeader":"<!-- begin field 13e01a8c-3cc7-443e-8d5f-be3cb6a68f14 --><h3>When should I arrange emergency admission for someone with cough?</h3><!-- end field 13e01a8c-3cc7-443e-8d5f-be3cb6a68f14 -->","summary":null,"htmlStringContent":"<!-- begin item fe508f91-0855-4ac8-8523-32dd40fc74aa --><!-- begin field 3ffd55ad-86f3-4eb0-a60f-0ddb3a54a530 --><p><strong>Arrange emergency admission for people with cough who have:</strong></p><ul><li><strong>Clinical features of suspected pulmonary embolism</strong><strong> or pneumothorax.</strong> For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pulmonary-embolism/\">Pulmonary embolism</a>.</li><li><strong>Signs or symptoms of serious illness,</strong> including:<ul><li>Respiratory rate of more than 30 breaths per minute. </li><li>Tachycardia greater than 130 beats per minute.</li><li>Systolic blood pressure less than 90 mmHg.</li><li>Oxygen saturation less than 92%, or central cyanosis (if the person has no history of chronic hypoxia).</li><li>Peak expiratory flow rate less than 33% of predicted. </li><li>Altered level of consciousness. </li><li>Use of accessory muscles of respiration (particularly if the person is becoming exhausted). </li></ul></li><li><strong>Clinical features of foreign body aspiration,</strong> or arrange urgent referral using clinical judgement.</li></ul><!-- end field 3ffd55ad-86f3-4eb0-a60f-0ddb3a54a530 --><!-- end item fe508f91-0855-4ac8-8523-32dd40fc74aa -->","subChapters":[{"id":"7e2f1dd2-5bb0-5838-9b77-db0fda97f3f0","slug":"basis-for-recommendation-555","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b1d6b6c4-547a-4285-ab4b-f7c21e29cd3d --><h4>Basis for recommendation</h4><!-- end field b1d6b6c4-547a-4285-ab4b-f7c21e29cd3d -->","summary":null,"htmlStringContent":"<!-- begin item 5555a014-2c79-4a0e-8aec-2de2969cc146 --><!-- begin field cbebc9c7-f085-490a-a353-1df3e740f469 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Venous thromboembolic diseases: diagnosis, management and thrombophilia testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">NICE, 2020b</a>]<crossref-tooltip data-referenceid=\"46e0d25c-c445-4c11-b859-d3db67ca79a2\" data-cross-reference-target=\"Dossier\" data-cross-reference-target-deleted=\"False\" data-cross-reference-target-link=\"/authoring/ffd98814-82a6-44ba-817f-ab8b00f0ff8b/edit/93c1cc2d-3aaa-4c82-b12e-ab8b00f101d7/project/28303e55-43ef-4421-bb4a-d2d1f7ab8e85\" data-cross-reference-type=\"Citation\"><span property=\"bibo:Article\"> <span property=\"bibo:authorList\">NICE</span> (<span property=\"dcterms:issued\">2020</span>) <span property=\"dc:title\">Venous thromboembolic diseases: diagnosis, management and thrombophilia testing.</span> National Institute for Health and Care Excellence. <span rel=\"bibo:Website\"><a href=\"http://www.nice.org.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"5a475696-50da-4f0d-88a0-ab9600dce06c\">www.nice.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"http://www.nice.org.uk/guidance/ng158\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"4fe4cd63-e98b-41f0-a4a6-ab9600dce09a\">Free Full-text</a></span>]</span></crossref-tooltip>, the Scottish Intercollegiate Guidelines Network (SIGN) and British Thoracic Society (BTS) <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">British guideline on th</em>e <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">management of asthma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">BTS/SIGN, 2019</a>]<em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">,</em> the BTS <em>Annotated BTS Guideline for the management of CAP in adults 201</em>5 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">BTS, 2015</a>], the Royal College of Physicians (RCP) report <em>National early warning score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">RCP, 2017</a>], and expert opinion in a narrative review <em>Chronic Cough</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Smith, 2016</a>].</p><!-- end field cbebc9c7-f085-490a-a353-1df3e740f469 --><!-- end item 5555a014-2c79-4a0e-8aec-2de2969cc146 -->","subChapters":[]}]},{"id":"b1c92c75-dbe7-5ac7-9b59-cc952edd638d","slug":"acute-cough","fullItemName":"Acute cough","depth":3,"htmlHeader":"<!-- begin field 17c607a2-1718-4174-a813-ab9600d48446 --><h3>How should I manage someone with acute cough?</h3><!-- end field 17c607a2-1718-4174-a813-ab9600d48446 -->","summary":null,"htmlStringContent":"<!-- begin item 44fa4d0e-dfa0-4d5d-98f5-ab9600d483ce --><!-- begin field 84d228a1-3a25-4e60-b5e5-ab9600d48446 --><p><strong>If the person with acute cough does not need emergency admission and has clinical features of:</strong></p><ul><li><strong>Upper respiratory tract infection</strong><ul><li>Advise them: <ul><li>That acute cough usually persists for up to 3 or 4 weeks. </li><li>How to manage their symptoms with self-care (for example, paracetamol or ibuprofen for any associated pain). Be aware that some people may wish to try honey, pelargonium (a herbal medicine), or over the counter medicines that contain the expectorant guaifenesin or cough suppressants.  </li><li>To seek medical advice if symptoms worsen rapidly or significantly, do not improve in 3–4 weeks, or they become systemically very unwell. </li><li>That if they smoke, they should stop. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li></ul></li><li>Do not offer the following treatments unless the person has an underlying airways disease (for example, asthma):<ul><li>An oral or inhaled bronchodilator (for example, salbutamol).</li><li>An oral or inhaled corticosteroid. </li></ul></li><li>Do not offer a mucolytic (for example, acetylcysteine or carbocisteine).</li><li>Do not offer an antibiotic to people who are not systemically very unwell or at higher risk of complications.<ul><li>Give advice about why an antibiotic was not given. </li></ul></li><li>For people identified at a face-to-face clinical examination as systemically very unwell, offer an immediate antibiotic — doxycycline 200 mg on the first day, then 100 mg once daily for 4 days (avoid in pregnancy). Or if this is not suitable, alternatives are:<ul><li>Amoxicillin 500 mg three times daily for 5 days.</li><li>Clarithromycin 250 mg to 500 mg twice daily for 5 days.</li><li>Erythromycin 250 mg to 500 mg four times daily (or 500 mg to 1000 mg twice daily) for 5 days.</li></ul></li><li>For people identified as at higher risk of complications, consider:<ul><li>An immediate antibiotic.</li><li>A back-up antibiotic prescription — give advice that it is not needed immediately and to use it if symptoms worsen rapidly or significantly at any time.</li></ul></li><li>When an antibiotic is given, give advice about possible adverse effects, particularly diarrhoea and nausea.</li></ul></li><li><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">COVID-19</strong> — follow the Public Health England advice for managing people with COVID-19 in primary care. For information on management, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/coronavirus-covid-19/\">Coronavirus - COVID 19</a>.</li><li><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Acute bronchitis or pneumonia</strong> — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chest-infections-adult/\">Chest infections - adult</a> for information on management.</li><li><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Acute exacerbation of asthma, chronic obstructive pulmonary disease (COPD), or bronchiectasis</strong> — see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/asthma/\">Asthma</a>, <a class=\"topic-reference external-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/\">Chronic obstructive pulmonary disease</a>, or <a class=\"topic-reference external-reference\" href=\"/topics/bronchiectasis/\">Bronchiectasis</a> for information on management.</li></ul><p><strong>Reassess people with an acute cough if their symptoms worsen rapidly or significantly, taking into account:</strong> </p><ul><li>Alternative diagnoses.</li><li>Any symptoms or signs suggesting a more serious illness or condition, such as cardiorespiratory failure or sepsis.</li><li>Previous antibiotic use, which may have led to resistant bacteria. </li></ul><!-- end field 84d228a1-3a25-4e60-b5e5-ab9600d48446 --><!-- end item 44fa4d0e-dfa0-4d5d-98f5-ab9600d483ce -->","subChapters":[{"id":"75143459-c477-5df4-8994-a002073e6481","slug":"basis-for-recommendation-8b3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 469d54d2-6c1a-454c-bc0f-ab9600d4844b --><h4>Basis for recommendation</h4><!-- end field 469d54d2-6c1a-454c-bc0f-ab9600d4844b -->","summary":null,"htmlStringContent":"<!-- begin item 8b334798-b665-4cc1-b215-ab9600d4844b --><!-- begin field b0797099-3eb4-491b-93ca-ab9600d4844b --><p>These recommendations are largely based on the (NICE) guideline <em>Cough (acute): antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">NICE, 2019a</a>]. </p><!-- end field b0797099-3eb4-491b-93ca-ab9600d4844b --><!-- end item 8b334798-b665-4cc1-b215-ab9600d4844b -->","subChapters":[]}]},{"id":"75553815-b863-5b61-b80c-9fe1c63fb723","slug":"sub-acute-or-chronic-cough","fullItemName":"Sub-acute or chronic cough","depth":3,"htmlHeader":"<!-- begin field bfa7620d-467d-470b-a714-ab9600d49ad7 --><h3>How should I manage someone with sub-acute or chronic cough?</h3><!-- end field bfa7620d-467d-470b-a714-ab9600d49ad7 -->","summary":null,"htmlStringContent":"<!-- begin item cf39afdd-fdfa-4779-bb63-ab9600d49a59 --><!-- begin field 6d9c39ff-c556-4616-b327-ab9600d49ad7 --><p><strong>Management of chronic cough may necessitate sequential trials of treatment (starting with the most likely aetiology first) to confirm or refute common causes.</strong> </p><ul><li><strong>If the person with sub-acute cough <strong>does not need emergency admission and </strong>has clinical features of post-infectious cough</strong> — explain that the cough is often self-limiting and usually lasts for no longer than 8 weeks (advise the person to re-attend for assessment if the cough does not improve after 2 months). Consider:<ul><li>A trial of inhaled ipratropium. </li><li>Inhaled corticosteroids if quality of life is affected and the cough persists despite use of inhaled ipratropium. </li><li>Oral prednisolone 30 mg to 40 mg daily for a short, finite period of time for severe paroxysms of post-infectious cough when other common causes of cough have been ruled out.</li><li>Centrally acting antitussives (such as codeine, or dextromethorphan) if other treatments fail. </li></ul></li><li><strong>If the person with chronic cough <strong>does not need emergency admission and </strong>has clinical features of:</strong><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitor-induced cough </strong>— stop the ACE inhibitor treatment and prescribe an alternative. For most people, the cough resolves within 1 month, but occasionally may persist for several months. For further information on alternative treatments, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\"> Hypertension - not diabetic</a>. </li><li><strong>Asthma </strong>— see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/asthma/\">Asthma</a> for information on management.</li><li><strong>Eosinophilic bronchitis </strong>— prescribe an inhaled corticosteroid first line. If symptoms do not improve, increase the dose of inhaled corticosteroid and consider prescribing a leukotriene inhibitor (for example, montelukast) after reconsidering other possible diagnoses.</li><li><strong>Gastro-oesophageal reflux disease</strong> — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-proven-gord/\">Dyspepsia - proven GORD</a> for information on management.  </li><li><strong>Smoking-related cough</strong> — advise people to stop smoking, but warn them that there may be a transient increase in coughing. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li><li><strong>Upper airway cough syndrome (post-nasal drip) </strong>— prescribe an antihistamine (for example, chlorphenamine) and a decongestant (for example, pseudoephedrine). Advise the person to avoid allergic or environmental triggers if possible, and that symptoms should improve within 1–2 weeks of starting treatment, but resolution may take several weeks and occasionally as long as a few months.<ul><li>If sinusitis coexists, manage appropriately. Treatment options include an intranasal corticosteroid (for example, mometasone) or antibiotic. For more information on management, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/sinusitis/\">Sinusitis</a>.</li><li>If rhinitis coexists, manage appropriately. First-line treatments include intranasal corticosteroids (for example, mometasone), intranasal antihistamines (for example, azelastine), or intranasal sodium cromoglicate. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/allergic-rhinitis/\">Allergic rhinitis</a>. </li></ul></li></ul></li><li><strong>If the person with cough does not need admission and has clinical features of:</strong><ul><li><strong>Bronchiectasis</strong> — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/bronchiectasis/\">Bronchiectasis</a> for information on management.</li><li><strong>Bronchitis </strong>— see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chest-infections-adult/\">Chest infections - adult</a> for information on management.</li><li><strong>Chronic obstructive pulmonary disease</strong> — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/\">Chronic obstructive pulmonary disease</a> for information on management.</li><li><strong>Cough-variant asthma</strong> — prescribe an inhaled corticosteroid first line. If symptoms do not improve, consider an alternative cause of cough, then increase the dose of inhaled corticosteroid, and consider: <ul><li>A therapeutic trial of a leukotriene inhibitor (for example, montelukast), <em>or</em></li><li>A beta-agonist (for example, salbutamol) in combination with the inhaled corticosteroid.   </li></ul></li><li><strong>Environmental or occupational causes </strong>— refer people to specialists with expertise in environmental and occupational disease to arrange appropriate objective tests to confirm an association between exposure and chronic cough. This may include methacholine challenge, sputum cytology, or immunologic tests.</li><li><strong>Heart failure</strong> — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a> for information on management.</li><li><strong>Interstitial lung disease (ILD)</strong> — refer people with ILD to secondary care for specialist management. </li><li><strong>Lung cancer</strong> — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/lung-pleural-cancers-recognition-referral/\">Lung and pleural cancers - recognition and referral</a> for information on management. </li><li><strong>Obstructive sleep apnoea  </strong>— see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a> for information on management. </li><li><strong>Pertussis (whooping cough)</strong> — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/whooping-cough/\">Whooping cough</a> for information on management. </li><li><strong>Pulmonary tuberculosis</strong> — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/tuberculosis/\">Tuberculosis</a> for information on management. </li><li><strong>Sitagliptin-induced cough </strong>— stop sitagliptin treatment. For more information on alternative treatments, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>. </li><li><strong>Somatic cough syndrome</strong> — refer the person for specialist assessment. </li></ul></li><li>If the cough does not respond to the trials of treatment, or partially responds (possibly indicating more than one cause), or the diagnosis is uncertain, refer the person to a respiratory physician for assessment.<ul><li>Treatment options for people with chronic refractory cough may include a trial of low dose morphine (5 mg to 10 mg twice daily), a trial of gabapentin, or a speech and language intervention. </li></ul></li></ul><!-- end field 6d9c39ff-c556-4616-b327-ab9600d49ad7 --><!-- end item cf39afdd-fdfa-4779-bb63-ab9600d49a59 -->","subChapters":[{"id":"a6e56e96-36b2-501b-bea4-21367d539ca1","slug":"basis-for-recommendation-15c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0936caf4-4b89-4714-81eb-ab9600d49ad9 --><h4>Basis for recommendation</h4><!-- end field 0936caf4-4b89-4714-81eb-ab9600d49ad9 -->","summary":null,"htmlStringContent":"<!-- begin item 15c96007-5a50-4ad4-8e8c-ab9600d49ad9 --><!-- begin field eeca148d-9f16-4f7a-97a1-ab9600d49ad9 --><p>These recommendations are based on the American College of Chest Physicians (CHEST) guidelines <em>Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Irwin, 2018</a>], <em>Somatic cough syndrome (previously referred to as psychogenic cough) and tic cough (previously referred to as habit cough) in adults and children</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Vertigan, 2015</a>], <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Managing chronic cough due to asthma and NAEB in adults and adolescents</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Côté, 2020</a>], <em>Occupational and environmental contributions to chronic cough in adults: chest expert panel repor</em>t [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Tarlo, 2016</a>], <em>An empiric integrative approach to the management of cough</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Pratter et al, 2006</a>], <em>Treatment of unexplained chronic cough: CHEST guideline and expert panel report</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Gibson, 2016</a>] and <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Postinfectious cough </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Braman, 2006</a>]; the European Respiratory Society (ERS) <em>ERS guidelines on the diagnosis and treatment of chronic cough in adults and children</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Morice, 2020</a>]; the National Institute for Health and Care Excellence (NICE) guideline <em>Idiopathic pulmonary fibrosis in adults: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">NICE, 2017</a>]; the British Medical Journal (BMJ) best practice guides <em>Assessment of chronic cough</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">BMJ, 2018a</a>] and <em>Upper airway cough syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">BMJ, 2018b</a>]; and expert opinion in a narrative review <em>Chronic cough: a practical approach to assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Mathur, 2019a</a>]. </p><h5>Sequential treatment </h5><ul><li>Even after a thorough clinical assessment, it may be impossible to identify which of the treatable traits is most likely to underlie the person's chronic cough [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Morice, 2020</a>]. <ul><li>The ERS guideline recommends short-term trials (2–4 weeks) of inhaled corticosteroid (ICS) in adults with chronic cough, a leukotriene inhibitor (especially for people with asthmatic cough), and an ICS and long-acting bronchodilator combination in adults with chronic cough and fixed airflow obstruction.</li><li>The guideline panel considered that it was preferable to undertake sequential therapeutic trials of each agent in turn and stop therapy if no responses were observed.</li><li>If treatment is successful it can be continued for several months after which it can be withdrawn to determine whether remission has occurred.</li></ul></li><li>If clinical review, chest X-ray, and spirometry fail to lead to a specific diagnosis, sequential trials of treatment may be considered to confirm or refute common causes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Mathur, 2019a</a>].<ul><li>Following clinical assessment, treatment for the most likely diagnosis (or diagnoses) should be started.</li><li>It may be preferable to initiate only one treatment at a time to determine its effects on follow up.</li><li>If clinical evaluation does not lead to an obvious cause, a sequential treatment trial for asthma, gastro-oesophageal reflux disease, and then upper airway cough syndrome should be considered.</li></ul></li><li>A careful history, along with selected therapeutic trials and/or diagnostic evaluations performed in a systematic and informed way, may satisfactorily resolve cough in over 90% of cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">BMJ, 2018a</a>].</li></ul><h5>Post-infectious cough</h5><ul><li>The CHEST guideline on <em>Postinfectious cough</em> recommends considering [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Braman, 2006</a>]:<ul><li>A trial of inhaled ipratropium as it may attenuate the cough.</li><li>Inhaled corticosteroids if quality of life is adversely affected and the cough persists despite use of inhaled ipratropium.</li><li>Oral prednisolone 30 mg to 40 mg daily for a short, finite period of time for severe paroxysms of post-infectious cough.</li><li>Centrally acting antitussives (such as codeine or dextromethorphan) if other treatments fail. </li></ul></li><li>The recommendation to advise the person to return if post-infectious cough does not resolve after 8 weeks is pragmatic as it is normally self-limiting and if it persists for longer than 8 weeks further evaluation is indicated to consider alternative diagnoses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">BMJ, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Braman, 2006</a>].</li></ul><h5>Eosinophilic bronchitis</h5><ul><li>The recommendation to prescribe an inhaled corticosteroid or leukotriene inhibitor is based on the CHEST guideline <em>Managing chronic cough due to asthma and NAEB in adults and adolescents</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Côté, 2020</a>], the BMJ best practice guide <em>Assessment of chronic cough </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">BMJ, 2018a</a>] and the ERS guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Morice, 2020</a>].<br><ul><li>Cough due to non-asthmatic eosinophilic bronchitis (NAEB) improves after a course of inhaled steroids for 4–6 weeks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">BMJ, 2018a</a>], however, ERS recommends that if there has been no treatment response in 2–4 weeks the empirical trial should be stopped [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Morice, 2020</a>].</li></ul></li><li>A narrative review advises that eosinophilic bronchitis may partially respond to inhaled corticosteroids, but a systemic steroid trial (oral prednisolone) may be required to establish the diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Mathur, 2019a</a>]. </li></ul><p><strong>Upper airway cough syndrome (UACS)</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Pratter et al, 2006</a>]</p><ul><li>The CHEST guideline recommends using a first-generation antihistamine and a decongestant to treat UACS. However, if an underlying cause is identified (such as allergic rhinitis or sinusitis), specific therapy should be directed at treating those conditions.  </li><li>Noticeable improvement in cough is usually seen within days to 1–2 weeks of initiating therapy. Marked improvement or resolution of cough may take several weeks and occasionally as long as a few months.</li></ul><p><strong>Cough-variant asthma</strong></p><ul><li>These recommendations are based on the CHEST guideline <em>Managing chronic cough due to asthma and NAEB in adults and adolescents</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Côté, 2020</a>] and the ERS guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Morice, 2020</a>].<ul><li>ERS recommends that if there has been no treatment response in 2–4 weeks the empirical trial should be stopped [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Morice, 2020</a>].</li></ul></li></ul><h5>Environmental or occupational causes</h5><ul><li>These recommendations are based on the CHEST guideline <em>Occupational and environmental contributions to chronic cough in adults</em>, and expert opinion in a narrative review.<ul><li>It would be appropriate to consider allergy testing as well as an evaluation of the patient’s home and workplace if there is a potential environmental cause for persistent upper airway symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Pratter et al, 2006</a>].</li><li>CHEST recommends that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Tarlo, 2016</a>]:<ul><li>If the history is suggestive of an occupational or environmental association it should be confirmed when possible by objective testing, in order to maximize favourable patient outcomes and determine the incidence of occupational and environmental causes of chronic cough.</li><li>For people with chronic cough and occupational or environmental exposure history, appropriate objective tests should be performed to elucidate potential mechanistic associations between cough and the suspected exposure.</li><li>People with chronic cough and a high suspicion of cough due to environmental and/or occupational exposures should be managed according to evidence-based guidelines for these exposures and/or be referred to specialists with expertise in environmental and occupational disease. </li></ul></li></ul></li></ul><h5>Interstitial lung disease</h5><ul><li>The recommendation to refer people with suspected interstitial lung disease to secondary care is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Idiopathic pulmonary fibrosis in adults: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">NICE, 2017</a>].</li></ul><h5>Somatic cough</h5><ul><li><p>The CHEST guideline on <em>Somatic cough syndrome</em> makes no treatment recommendations for adults with somatic cough [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Vertigan, 2015</a>]. CKS recommends referring people with features of somatic cough for specialist evaluation.</p></li></ul><h5>Refractory cough</h5><ul><li>The CHEST guideline <em>Treatment of unexplained chronic cough</em> recommends referral to a specialist cough clinic as an option for difficult to treat cough.<ul><li>Other options include speech and language intervention, or a trial of gabapentin treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Gibson, 2016</a>]. </li></ul></li><li>The British Thoracic Society guideline recommends that people with chronic cough should be referred to a specialist centre if the diagnosis is in doubt, or when there has been a failure of empirical treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Morice et al, 2006</a>].</li><li>People who do not respond to empirical treatment may merit secondary care referral to respiratory medicine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Mathur, 2019a</a>].</li><li>The ERS guideline recommends trials of low-dose morphine, gabapentin, or pregabalin and cough control therapy for people with chronic refractory cough [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough/references/\">Morice, 2020</a>].</li></ul><!-- end field eeca148d-9f16-4f7a-97a1-ab9600d49ad9 --><!-- end item 15c96007-5a50-4ad4-8e8c-ab9600d49ad9 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}